NIH scientists from the United States in the international academic journals published a new study progress, they reported that injection called VRC01 potent antibodies can be suppressed not receiving antiretroviral therapy for HIV in the blood of HIV carriers Level. The researchers also found that by intravenous or subcutaneous injection manner VRC01 HIV antibody in vivo has a very good safety and tolerability and injection antibody can be maintained for a long time in the patient's blood.
Scientists led Phase I clinical trials including a total of 23 HIV carriers, of which 15 were receiving antiretroviral therapy, eight others received no treatment. Researchers treated with HIV antibodies were injected twice, but did not receive antiretroviral therapy carriers only accept the first antibody injection, researchers then antibody injection safety and can reduce plasma and blood cells viral load were assessed.
The researchers found that although the antibody injection did not reduce the amount of HIV in blood cells, but did not receive antiretroviral therapy 6 out of 8 in plasma viral load dropped by more than 10-fold decrease in viral load in patients They started the study when the least amount of carrying the virus, and after antibody injection, HIV virus to maintain effective antibody concentration in nearly three weeks was suppressed at an extremely low level, a significant decline in viral load rest of 4 people, but It did not fall to undetectable levels. And after receiving antibody treatment detected but no change in viral load in the body of the other two types can carry the HIV virus resistant to VRC01 antibody production. Patients who have received anti-retroviral therapy in vivo inhibition of HIV has been accepted antibody injection did not show any other effect.
